24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Blood Cancer
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:24
Full list of Israeli high-tech layoffs in 2026
13:22
Wix to cut 1,000 jobs in largest layoff round in company history
12:08
Base44 is booming. So why is Wix collapsing?
11:51
Israel’s security reality is growing more dangerous, and more expensive
More stories
Buzz
Most popular
Daily
Weekly
1
Project Glasswing by Anthropic didn't just find the bugs. It also found the real vulnerability in cybersecurity.
2
The giant models threaten to wipe out classic cybersecurity companies. Who will survive the revolution?
3
Cyber unicorn Cyera acquires five-month-old startup Genie Security in $50 million deal
4
China’s EV giants are colliding with Israel’s security concerns
5
Israel’s tech boom faces an unexpected threat: Its own currency
More news
Blood Cancer
4 stories about Blood Cancer
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
24.12.18
|
Lilach Baumer
The investment is part of a licensing option agreement signed between the two companies
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18
|
Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000